Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Blood (2023) 142 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2023-190590

Published: 2023

Journal Articles

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Marcelo Pitombeira de Lacerda, Fernanda de Morais Marques, Verena Pfister, Flavia de Carvalho Parra, Vinicius Campos de Molla, Valeria Buccheri, Rafael Dezen Gaiolla, Laura Maria Fogliatto, Rodrigo Santucci, Marcelo Bellesso, Sérgio Costa Fortier, Talita M.B. Silveira, Glaciano Ribeiro, Nelson Hamerschlak, Mihoko Yamamoto, Matheus Vescovi Goncalves, Carlos S. Chiattone, Celso Arrais-Rodrigues

Blood (2022) 140 (Supplement 1): 7041–7042.

https://doi.org/10.1182/blood-2022-170872

Published: 2022

Journal Articles

Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Renato Torrescasana Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Daniela Ferreira Dias, Israel Bendit, Jhony ARANHA Lima Alves, Felipe Ribeiro Bruniera, Ariel Testasicca Trunkel, Adelson Alves da Silva, Sr.

Blood (2022) 140 (Supplement 1): 12226–12227.

https://doi.org/10.1182/blood-2022-157425

Published: 2022

Journal Articles

Retrospective Evaluation of Real-World Treatment Patterns in Patients with Mantle Cell Lymphoma - REALM in a Single Brazilian Center

Marcelo Bellesso, Rodrigo Santucci, Renato Torrescasana Centrone, Daniela Ferreira Dias, Mariana Nascimento Caiaffo Rodrigues, Luana Correa Travassos, Iohanã Gabriely Costa Oliveira, Tamyres Alves Gomes, Caroline Jorge Espadas, Joyce Barreto Marques da Rosa Ferreira, Bruno Santucci, Adelson Alves

Blood (2022) 140 (Supplement 1): 11972–11973.

https://doi.org/10.1182/blood-2022-164590

Published: 2022

Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution

Renato Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Joyce Barreto Marques da Rosa Ferreira, Iohanã Gabriely Costa Oliveira, Luana Correa Travassos, Caroline Jorge Espadas, Tamyres Alves Gomes, Mariana Nascimento Caiaffo Rodrigues, Adelson Alves Silva

Blood (2022) 140 (Supplement 1): 7954–7955.

https://doi.org/10.1182/blood-2022-157148

Published: 2022

Journal Articles

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Vinicius Campos de Molla, MD, Ana Rita Da Fonseca, MD, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Guilherme Brasil Duffles Amarante, MD, Valeria Buccheri, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142810

Published: 2020

Journal Articles

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142520

Published: 2020

Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD

Blood (2019) 134 (Supplement_1): 5847.

https://doi.org/10.1182/blood-2019-128629

Published: 2019

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Jeff Sharman, MD, Anna Marina Liberati, MD, Rodrigo Santucci Silva, MD, Igor Aurer, MD PhD, Jeffery Robbins, MS, Julie Ann Rosenberg, MD, Tahira Khan, MD MS, Ann Alcasid

Blood (2018) 132 (Supplement 1): 394.

https://doi.org/10.1182/blood-2018-99-111248

Published: 2018

Journal Articles

Superiority of Triple Combination Bortezomib + Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide + Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients

Blood (2017) 130 (Supplement 1): 5527.

https://doi.org/10.1182/blood.V130.Suppl_1.5527.5527

Published: 2017

Journal Articles

Decentralized Data Storage to Promote Epidemiological Analysis for Subtypes Non Hodgkin Lymphoma

Marcelo Bellesso, MD, Renato Centrone, MD, Daniela Ferreira Dias, MD, Rodrigo Santucci, MD

Blood (2016) 128 (22): 2386.

https://doi.org/10.1182/blood.V128.22.2386.2386

Published: 2016

Journal Articles

Long-Term Use of Azacitidine in Private Practice in Brazil: An Analysis of Patients Profiles

Renato Centrone, MD, Laura Yolanda Chialanza Garcia, MD, Rodrigo Santucci, MD, Marcelo Bellesso, MD

Blood (2016) 128 (22): 5556.

https://doi.org/10.1182/blood.V128.22.5556.5556

Published: 2016

Journal Articles

Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue

Shana Traina, PhD, Graeme Fraser, MDFRCPC, Paula Cramer, MD, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Marie Sarah Dilhuydy, MD, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD

Blood (2015) 126 (23): 267.

https://doi.org/10.1182/blood.V126.23.267.267

Published: 2015

Journal Articles

Fight for Platelets: AML Diagnosed during Dengue Fever: Case Report

Laura Yolanda Chialanza Garcia, MD, Daniela Ferreira Dias, MD, Marcelo Bellesso, MD, Juliano Cordova Vargas, MD, Milton A. F. Aranha, MD, Annelise C. Wengerkievicz Lopes, MD, Rodrigo Santucci, MD

Blood (2015) 126 (23): 4903.

https://doi.org/10.1182/blood.V126.23.4903.4903

Published: 2015

Journal Articles

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Blood (2015) 126 (23): 469.

https://doi.org/10.1182/blood.V126.23.469.469

Published: 2015

Journal Articles

Cyclic Thrombocytopenia: A Case Report

Leila P. S. Fontenele, MD, Rodrigo Santucci, MD, Renato Centrone, MD, Milton A. F. Aranha, MD, Marcelo Bellesso, MD, Daniela Ferreira Dias, MD

Blood (2015) 126 (23): 4661.

https://doi.org/10.1182/blood.V126.23.4661.4661

Published: 2015

Journal Articles

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Asher Chanan-Khan, MD, Paula Cramer, MD, Graeme Fraser, MDFRCPC, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Aleksander Pristupa, MD, Marie Sarah Dilhuydy, MD, Andre Goy, MD, Anthony R. Mato, MD MSCE, Rajendra Damle, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Angela Howes, PhD, Sriram Balasubramanian, PhD

Blood (2015) 126 (23): 1732.

https://doi.org/10.1182/blood.V126.23.1732.1732

Published: 2015

Journal Articles

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Georg Hess, MD, Simon Rule, MD, Wojciech Jurczak, Mats Jerkeman, MD PhD, Rodrigo Santucci, MD, Chiara Rusconi, MD, Dolores Caballero, Cristina M. Joao, MD PhD, Mathias Witzens-Harig, MD, Isabelle Bence-Bruckler, MD FRCPC, Seok-Goo Cho, Nibedita Bandyopadhyay, PhD, Jenna Goldberg, MD, John Bothos, PhD, Christopher Enny, BS, Jessica Vermeulen, MD PhD, Shana Traina, PhD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 1542.

https://doi.org/10.1182/blood.V126.23.1542.1542

Published: 2015

Journal Articles

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2015) 126 (23): 2938.

https://doi.org/10.1182/blood.V126.23.2938.2938

Published: 2015

NARROW

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Retrospective Evaluation of Real-World Treatment Patterns in Patients with Mantle Cell Lymphoma - REALM in a Single Brazilian Center

Financial Impact of Imatinib Discontinuation in Brazil - a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Superiority of Triple Combination Bortezomib + Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide + Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients

Decentralized Data Storage to Promote Epidemiological Analysis for Subtypes Non Hodgkin Lymphoma

Long-Term Use of Azacitidine in Private Practice in Brazil: An Analysis of Patients Profiles

Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue

Fight for Platelets: AML Diagnosed during Dengue Fever: Case Report

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Cyclic Thrombocytopenia: A Case Report

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only